Endometrial cells on Pap tests: ideal reporting is more complex than just finding the right age.
The age for reporting normal endometrial cells (EMCs) on Pap tests was changed to ≥ 45 years in the latest Bethesda update (2014). This recommendation is solely based on age with no consensus on optimal reporting guidelines. Pap tests with EMCs for women ≥40 years were retrieved from our Laboratory Information System (LIS). Patient age, last menstrual period (LMP) and available follow-up histology were recorded. Follow-up diagnoses were categorized as: no significant pathology, benign, hyperplasia ± atypia, or malignant. The Fisher's exact test was used to assess the association between categorical variables, p < .05 (two-sided test) was considered significant. Of the 352 cases with EMCs, 155 had surgical follow-up. They showed no malignancy in the 89 women between 40-49 years, compared with five malignancies in the 66 women 50+ years (p = .016). The number of cases with significant pathology (hyperplasia and malignant) was 4 (40-49 years) vs. 11 (50+ years) (p = 0.029). The LMP was inconsistently provided (57%) and women identified as postmenopausal on requisition comprised all the malignancies and half the hyperplasias. Combined effort by pathologists and clinicians necessitates determining the best standardized clinicopathologic guidelines to report EMCs and appropriate follow-up. Increasing the required age to ≥50 years would provide more optimal patient management; however, there are other considerations beyond age. Reporting EMCs in postmenopausal women is a reasonable alternative requiring consistent and accurate recording of LMP. Improving provided information for pathologists, determining reporting requirements for EMCs and standardizing clinical follow-up should be a multidisciplinary effort. Diagn. Cytopathol. 2017;45:587-591. © 2017 Wiley Periodicals, Inc.